Basel-based startup Allegria has closed a USD 3.5 million seed financing round led by Forty51 Ventures to advance the research and development of its therapeutics for mast cell-mediated diseases. This news coincides with the appointment of co-founder Dr Maria van Dongen as the new CEO.
![USD 3.5 Million to tackle allergies and inflammatory diseases](https://republic-of-innovation.ch/wordpress/wp-content/uploads/2024/05/Allergies-630x338.jpg)